J. Michael Dixon

The value of adjuvant treatment in young women with breast cancer.

One stop clinics should not be abandoned.

Endocrine and clinical endpoints of exemestane as neoadjuvant therapy.

Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast cancer treatment.

Postcode prescribing is alive and well in Scotland.

Breast cancer: non-metastatic.

Message about hormone replacement therapy is unclear.

Breast cancer: non-metastatic.

Breast cancer (non-metastatic).

Exemestane and aromatase inhibitors in the management of advanced breast cancer.

Role of endocrine therapy in the neoadjuvant surgical setting.

The scientific value of preoperative studies and how they can be used.

Breast cancer (non-metastatic).

Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.

Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.

Surgical issues surrounding use of aromatase inhibitors.

Breast cancer (non-metastatic).

Translation elongation factor eEF1A2 is a potential oncoprotein that is overexpressed in two-thirds of breast tumours.

Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer.

Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer.

Neoadjuvant endocrine therapy models.

Screening for breast cancer.

The prevention, detection, and management of breast cancer.

Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial.

Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.

Extended adjuvant therapy with letrozole: reducing the risk of recurrence.

Proceedings of the Consensus Conference on Breast Conservation, April 28 to May 1, 2005, Milan, Italy.

Consensus conference on breast conservation.

Estrogen receptor alpha positive breast tumors and breast cancer cell lines share similarities in their transcriptome data structures.

Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced hormone receptor-positive breast cancer.

Aromatase inhibitors in early breast cancer therapy: a variety of treatment strategies.

Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.

Neoadjuvant use of endocrine therapy in breast cancer.

Molecular response to aromatase inhibitor treatment in primary breast cancer.

DCIS and aromatase inhibitors.

Aromatase inhibitors--gene discovery.

Breast abscess.

Predicting response and resistance to endocrine therapy: profiling patients on aromatase inhibitors.

Increase in response rate by prolonged treatment with neoadjuvant letrozole.

Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer.

Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.

Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer.

Reducing early recurrence with adjuvant aromatase inhibitors: what is the evidence?

Predictors of mastectomy in a certified breast center - the surgeon is an independent risk factor.

Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms.

Adjuvant endocrine therapy for perimenopausal women with early breast cancer.

Introduction to sessions on 'What can surgeons do for us (and we for them): radiology, pathology, molecular biology and local therapy'.

Extended follow-up of breast cancer patients in clinic wastes time for both patients and doctors: the case for.

Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features.

Magnetic resonance imaging screening of the contralateral breast in women with newly diagnosed breast cancer: systematic review and meta-analysis of incremental cancer detection and impact on surgical management.

A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.

Breast screening has increased the number of mastectomies.

Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors.

So you want to be ... a breast surgeon.

Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer.

Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial.

Correcting for intra-experiment variation in Illumina BeadChip data is necessary to generate robust gene-expression profiles.

Combining and sequencing adjuvant chemotherapy and tamoxifen in postmenopausal women with node-positive breast cancer.

Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer.

A further survey of surgical management of the axilla in UK breast cancer patients.

Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer.

对早期侵袭性乳腺癌患者保乳治疗局部复发的外科边距的影响的 Meta 分析。

Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability.

DCIS of the breast: Are we over-diagnosing it? Are we over-treating it?

Treatment of breast infection.

Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer.

Implant-Based Augmentation Mammaplasty Following Breast Conservation Surgery.

Transcriptionally repressed genes become aberrantly methylated and distinguish tumors of different lineages in breast cancer.

Invasive lobular carcinoma: response to neoadjuvant letrozole therapy.

Constructing tissue microarrays from core needle biopsies of breast cancers.

Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer.

Determining tamoxifen sensitivity using primary breast cancer tissue in collagen-based three-dimensional culture.

Tissue type is a major modifier of the 5-hydroxymethylcytosine content of human genes.

Relative impact of key sources of systematic noise in Affymetrix and Illumina gene-expression microarray experiments.

Congenital abnormalities of the breast.

Impact of Screening and Risk Factors for Local Recurrence and Survival After Conservative Surgery and Radiotherapy for Early Breast Cancer: Results from a Large Series with Long-Term Follow-Up.